Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - Zymeworks Inc. | d900170dex991.htm |
| EX-4.1 - EX-4.1 - Zymeworks Inc. | d900170dex41.htm |
| 8-K - 8-K - Zymeworks Inc. | d900170d8k.htm |
Exhibit 99.2
FORM 51-102F3
MATERIAL CHANGE REPORT
| Item 1: | Name and Address of Company |
Zymeworks Inc. (“Zymeworks” or the “Company”)
1385 West 8th Avenue, Suite 540
Vancouver, BC, Canada
V6H 3V9
| Item 2: | Date of Material Change |
March 16, 2020
| Item 3: | News Release |
A news release announcing the material change was disseminated through the facilities of Business Wire on March 16, 2020 and a copy was filed on the Company’s profile at www.sedar.com.
| Item 4: | Summary of Material Change |
On March 16, 2020, Zymeworks announced the appointment of Kelvin Neu, M.D., to its Board of Directors.
| Item 5: | Full Description of Material Change |
5.1 Full Description of Material Change
On March 16, 2020, Zymeworks announced the appointment of Kelvin Neu, M.D., to its Board of Directors.
Dr. Neu is a Partner at Baker Bros. Advisors LP, a long term life-sciences investment firm. Kelvin earned his M.D. from the Harvard Medical School-MIT Health Sciences and Technology program after spending three years in the Immunology Ph.D. program at Stanford University as a Howard Hughes Medical Institute Fellow. Dr. Neu holds an A.B. (summa cum laude) from Princeton University, where he was awarded the Khoury Prize for graduating first in his department of Molecular Biology. He also serves as Director of Prelude Therapeutics, Inc. and IGM Biosciences, Inc.
5.2 Disclosure of Restructuring Transactions
Not applicable.
| Item 6: | Reliance on subsection 7.1(2) of National Instrument 51-102 |
Not applicable.
| Item 7: | Omitted Information |
Not applicable.
| Item 8: | Executive Officer |
For further information, please contact Neil Klompas, Executive Vice President, Business Operations and Chief Financial Officer of the Company at (604) 678-1388.
| Item 9: | Date of Report |
March 16, 2020